Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Citron Research

Elon Musk's Two-Word Response, Trump Administration's Patent Share, Palantir CEO's China Warning And More: This Week In Politics

It’s been an eventful week, with some of the most influential figures in the business world making headlines. Here’s a quick recap of the top political stories you might have missed.

Benzinga

Trump-Linked Mortgage Trade? Citron Says This Stock Is A Soldier In 'War On Housing' — Predicts 91% Upside

Andrew Left’s Citron Research is making a bold new bet in the housing finance space, framing it as a deep-value play, and one that is likely to play a central role in President Donald Trump’s new housing policy.

Benzinga

Short Seller Andrew Left Recalls Bet On Nebius As It Soars Over 130% In 2025: 'Just A Pat On The Back' From When NBIS Was At $20 Per Share

Famed short-seller Andrew Left of Citron Research is taking a victory lap on a bullish call, celebrating his firm’s early bet on AI infrastructure company Nebius Group NV (NASDAQ:NBIS).

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Martin Shkreli Doubles Down On Opendoor 'Short' Call: 'Pharma-Bro' Draws Parallels With Newegg — 'Game Over Losers'

Former hedge fund manager and pharmaceutical executive, Martin Shkreli, doubled down on his bearish stance against Opendoor Technologies Inc. (NASDAQ:OPEN), drawing parallels with another retail favorite stock that has since witnessed a pullback.

Benzinga

Palantir's AI Edge: PEG Ratio Outshines Salesforce—'Sleeper Valuation' Defying P/E Skeptics?

In a landscape where high Price-to-Earnings (P/E) ratios often scare investors, a different metric defies skeptics that AI powerhouse, Palantir Technologies Inc. (NASDAQ:PLTR), which was battered last week for its high valuations following a Citron Research report, is not quite overpriced.

Benzinga

Palantir's 70x Revenue Valuation May Be Unsustainable Despite 'Outstanding Q2 Results' — Citi Analyst Warns Company's 'Edge' May Fade As AI Expands

According to Tyler Radke, a senior Citigroup equity analyst, Palantir Technologies Inc.’s (NASDAQ:PLTR) lofty valuations are difficult to justify despite its “outstanding Q2 results.”

Benzinga

Palantir Short Seller Andrew Left's Citron Now Compares It To Databricks: 'PLTR Is A $40 Stock, And Every Real AI Leader Keeps Reminding Us'

Short-seller Andrew Left‘s Citron Research intensified its campaign against Palantir Technologies Inc. (NYSE:PLTR) on Wednesday, posting a direct comparison to private competitor Databricks that highlights Palantir’s slower growth on several key metrics.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Short Seller Andrew Left Says 'OpenAI At $500 Billion Puts Palantir At $40' — And That's Generous

Renowned short-seller Andrew Left's Citron Research has issued a bearish report on Palantir Technologies Inc. (NASDAQ:PLTR), arguing the stock is significantly overvalued and its price is "detached from fundamentals and analysis".

Benzinga

Citron Research Just Warned AGAIN on Palantir. How Should You Play PLTR Stock Here?

Citron Research says Palantir stock at $40 per share would still be an expensive AI stock to own. Wall Street recommends caution on PLTR shares as well.

Barchart

Short Seller Slams Jim Cramer Over Palantir, Accuses Him Of Hyping 'High-Multiple, Hype-Driven Narrative' After $200 Price Target Call

Famed short-seller Andrew Left's Citron Research publicly challenged CNBC's Jim Cramer over his bullish stance on Palantir Technologies Inc. (NASDAQ:PLTR).

Benzinga

GameStop Short Seller Andrew Left Is Taking On Retail Investors Again, Now Says Palantir Stock Is 'Beyond Overvalued'

Citron Research founder and famed short seller Andrew Left announced a new short pick on Wednesday during an appearance on Fox Business.

Benzinga

Andrew Left Doubles Down On Rocket Companies: 'This Isn't A Meme,' It's A 'Housing Juggernaut' In The Making (CORRECTED)

Editor's Note: This article has been updated to correct the individual’s name in the headline.

Benzinga

Teladoc Stock Is a ‘Coiled Spring’ That Could Surge Higher. Should You Buy TDOC Here?

Teladoc stock gains as Citron Research posts a bullish report in its favor. Wall Street remains positive on TDOC shares for the second half of 2025 as well.

Barchart

Citron Research Just Identified This 1 Stock to Buy as a ‘Hidden’ AI Winner

Former short seller Citron Research is growing bullish on Teladoc's growth potential.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Andrew Left's Citron Research Says Nvidia-Backed Nebius Is The Next 'AI Wall Street Darling' — Stock Moves Up 14%

Shares of Nebius Group NV (NASDAQ:NBIS) jumped 13.90% on Tuesday after Citron Research highlighted the company’s potential to become the next artificial intelligence sensation on Wall Street, citing its deep ties with NVIDIA Corp. (NASDAQ:

Barchart

Here's How High MicroStrategy Stock Can Climb as Bitcoin Races to New Highs

In the past five years, MicroStrategy's massive exposure to Bitcoin has allowed share prices to surge over 2,000%. Can the tech stock continue to surge in 2025?

Benzinga

'Pharma Bro' Martin Shkreli Tells Investors To 'Short SAVA,' Stock Falls Over 80% After Phase 3 Update

Pharma bro Martin Shkreli predicted Cassava Sciences stock would fall and the company would miss primary endpoints for its Phase 3 trial.

Top News

Short Seller Andrew Left Charged With Securities Fraud Scheme

Short seller Andrew Left charged with securities fraud for manipulating stock prices through Citron Research. SEC also pursuing charges in a million fr...

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

GameStop Stock Reverses, Top Short Seller Bows Out On 'Mob Mentality'

GameStop stock short seller Citron Research exited GME, citing the retailer's swelling cash coffers and "cult-like" investor following.

Fortune

Short-seller Andrew Left is betting against GameStop again, undaunted by his 100% loss last time

When meme-stock traders' de facto leader posted a screenshot implying he owns over $100 million of GameStop, Andrew Left immediately shorted the stock.

Investors Business Daily

GME Stock Tumbles On Q1 Preview, Top Short Seller Returns; Robinhood Sees Major Upgrade

GME stock tumbles after GameStop's preliminary Q1 results disappoint. A major short seller returns. Robinhood sees double upgrade. Meme rally fizzles.

Zenger

Citron Research Founder Andrew Left Lives In Fear Amidst GameStop Fallout

Left worries about potential charges as federal agencies probe activist short sellers

Benzinga

Why This Short Seller Is Doubling Down Against Cryptocurrency, Says 'US Government Should Be Embarrassed' About FTX Debacle

Activist investor and short seller Citron Research made headlines in 2021 for attacking stocks like GameStop Corporation (NYSE: GME) and other popular companies with the retail investment crowd.

Benzinga

Crypto Bull Kevin O'Leary Vs. Bear Andrew Left: Who Will Win The Tug of War?

Even as the cryptocurrency market on Monday reclaimed the $1 trillion market cap following a dramatic fall in prices of late, there could be more pain ahead for investors in the short term, according to experts.

Benzinga

EXCLUSIVE: Short Seller Andrew Left Says The Idea Of Decentralization Is The 'Stupidest Thing Ever'

Andrew Left, founder of Citron Research says the idea of decentralization, where power is shifted from the hands of centralized entities is the “stupidest thing ever” and pointed out that the only utility Bitcoin has is that it is a collective consciousness of people, with people buying because others are.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Justice Department

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.